Denali reports Q3 net loss $99.4M; cuts 2023 expense growth outlook to 15-20%

Denali Therapeutics Inc.

2023-Q3 EPS reported -$0.19 revenue$330,531,000

Net loss $99.4M (vs $103.3M); revenue $1.3M (vs $3.6M). Cash $1.12B.
FY2023 cash op expense growth guidance reduced to 15-20% from prior 25-30%.
Sanofi's eclitasertib failed CLE Phase 2; UC study continues. Biogen amended LRRK2 deal.
Pipeline: DNL310 Phase 2/3 enrolling; DNL126 Phase 1/2 starting; OTV advancing 2 candidates to clinic.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Denali Therapeutics Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 7, 2023, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Denali Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001714899-23-000145

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.